Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy
Henrik Svedsäter(GlaxoSmithKline (United Kingdom)), Scott Berry(Queen's University), David Leather(GlaxoSmithKline (United Kingdom)), Jaro Wex(GlaxoSmithKline (United Kingdom)), Michelle A. Detry(Berry & Associates (United States)), G. Stynes(GlaxoSmithKline (United Kingdom)), Lucy Frith(GlaxoSmithKline (United Kingdom)), E Castelnuovo(GlaxoSmithKline (United Kingdom))
Cited by 11
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951